EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nuo Therapeutics's EBITDA for the
three
months ended in Mar. 2026 was $-0.41 Mil. Nuo Therapeutics's Revenue for the
three
months ended in Mar. 2026 was $1.30 Mil. Therefore, Nuo Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was -31.11%.
Nuo Therapeutics (OTCPK:AURX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nuo Therapeutics EBITDA Margin % Related Terms
Nuo Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Nuo Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AURX vs ACTU, ESLA, LTRN: EBITDA Margin % Comparison
For the Biotechnology subindustry, Nuo Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuo Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nuo Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuo Therapeutics (AURX) has a EBITDA Margin % of -31.11% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nuo Therapeutics and its competitors. According to the industry distribution chart, Nuo Therapeutics ranks #450 out of 944 companies in the Biotechnology industry, placing it in the top 47.7%.
Is Nuo Therapeutics' EBITDA Margin % too high?
Nuo Therapeutics' current EBITDA Margin % is -31.11%. Based on the distribution chart, Nuo Therapeutics ranks #450 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nuo Therapeutics has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nuo Therapeutics' EBITDA Margin % compare to ACTU and ESLA?
According to the Biotechnology industry distribution chart, Nuo Therapeutics ranks #450 out of 944 companies for EBITDA Margin %. This puts Nuo Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nuo Therapeutics and its competitors. Nuo Therapeutics's current EBITDA Margin % is -31.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nuo Therapeutics (AURX) is currently considered Possible Value Trap. The stock's GF Value™ is $4.23, compared to a current price of $1.01 — trading 76.1% below its estimated fair value. The current EBITDA Margin % is -31.11%. Nuo Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nuo Therapeutics (AURX), the current EBITDA Margin % is -31.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nuo Therapeutics (AURX) Overvalued in 2026?
Based on GuruFocus' analysis, Nuo Therapeutics stock appears to be undervalued.
The current stock price of $1.01 is trading 76.1% below its estimated GF Value™ of $4.23.
GuruFocus considers Nuo Therapeutics to be Possible Value Trap.
Key valuation signals for AURX:
EBITDA Margin %: -31.11%
GF Value™: $4.23 vs. price of $1.01 (76.1% below fair value)
No single metric tells the full story. See the AURX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nuo Therapeutics Inc is a commercial-stage medical device company engaged in developing and marketing products for chronic wound care. The company operates as a single segment focused on regenerative therapies that utilize autologous (patient-derived) biological materials to promote natural healing. Its primary commercial product is the Aurix System, a point-of-care technology that produces platelet-rich plasma (PRP) therapy from a patient's own blood for use in the treatment of chronic wounds.
33GF Score
Get the complete analysis for AURX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AURX has been successfully added to your 
